Company: VRCA
Filing Date: 2025-04-11
Form Type: PRE 14A
Source: 0001193125-25-079118
Chunk: 49

Company: Verrica Pharmaceuticals Inc.
Filing Date: 2025-04-11
Form: PRE 14A
Chunk 49
---
 reflects the prorated portion of his 2024 annual base salary. |

| (2) | Dr. Goldenberg’s employment with us terminated in March 2025. |

| (3) | Mr. White’s employment with us terminated in November 2024. |

| (4) | Mr. Bonaccorso’s employment with us terminated in August 2024. |

Annual Bonus We seek to motivate and reward our executives for achievements relative to our corporate goals and expectations for each fiscal year. Each named executive officer has a target bonus opportunity, defined as a percentage of his annual salary, as set forth below:

| Name                 |     | 2025 Target Bonus  
 as a Percentage of 
 Base Salary        |     |     |     | 2024 Target Bonus  
 as a Percentage of 
 Base Salary        |     |     |
| Jayson Rieger        |     |                    |     | 40% |     |                    |     | 40% |
| Christopher G. Hayes |     |                    |     | 45% |     |                    |     | 45% |
| Gary Goldenberg(1)   |     |                    |     | —   |     |                    |     | 40% |
| Ted White(2)         |     |                    |     | —   |     |                    |     | 60% |
| Joe Bonaccorso(3)    |     |                    |     | —   |     |                    |     | 40% |

| (1) | Dr. Goldenberg’s employment with us terminated in March 2025. |

| (2) | Mr. White’s employment with us terminated in November 2024. |

| (3) | Mr. Bonaccorso’s employment with us terminated in August 2024. |

To reinforce the importance of integrated and collaborative leadership, our executives’ bonuses have historically been solely based on company performance, and we did not include an individual performance component. For 2024, the corporate performance goals consisted of clinical development, compliance, regulatory and financial objectives. For 2024, our Compensation Committee determined that the corporate performance goals had been achieved at a 25% level in the aggregate and exercised its discretion not to pay cash bonuses for 2024 corporate performance. In addition, for 2025, the Compensation Committee approved a cash incentive program pursuant to which our executive officers have aggregate cash bonus opportunities as detailed below, which can be earned based on the